In analogy to the use in cutaneous melanoma (CM), ICB includes the antibodies anti-CTLA-4 (ipilimumab), anti-PD-1 (nivolumab, pembrolizumab), and the combination of anti-PD-1 with anti-CTLA-4 (dual ICB). Here, CTLA4 is linked to cutaneous mastocytosis.